Total Funding
60
79
Total FundingVenture - Series Unknown raised
Growth Score
-3 pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
61297
Keystone Bio is a nextgen PharmaBiome biotech that has identified and is targeting a "one of a kind Inflammapath ".
- Daniel Sindelar: Co-Founder & CEO
- Peter Nara: Founder & Chief Scientific OfficerPast Role: Lantern Pharma, Former Consultant
About the Company
Keystone Bio has identified and is targeting a "one of a kind Inflammapath ", the keystone pathogen of chronic inflammation that’s been shown to initiate and advance Atherosclerosis, Heart disease and Alzheimer's disease.
Keystone Bio is a nextgen PharmaBiome biotech that has identified and is targeting a "one of a kind
Inflammapath ", the keystone pathogen of chronic inflammation that’s been shown to initiate and advance Atherosclerosis, Heart disease and Alzheimer's disease.
